These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 10950769

  • 1. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA.
    J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
    [Abstract] [Full Text] [Related]

  • 2. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
    de Mendoza C, Valer L, Bacheler L, Pattery T, Corral A, Soriano V.
    AIDS; 2006 Apr 24; 20(7):1071-4. PubMed ID: 16603864
    [Abstract] [Full Text] [Related]

  • 4. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
    Mascolini M.
    J Int Assoc Physicians AIDS Care; 1997 Jun 24; 3(6):17-21. PubMed ID: 11364427
    [Abstract] [Full Text] [Related]

  • 5. Coming therapies: amprenavir.
    Gatell J.
    Int J Clin Pract Suppl; 1999 Jun 24; 103():42-4. PubMed ID: 10622044
    [Abstract] [Full Text] [Related]

  • 6. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC, Brumme ZL, Harrigan PR.
    J Virol; 2001 Jan 24; 75(2):589-94. PubMed ID: 11134271
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. What they say about protease inhibitors.
    Posit Aware; 1999 Jan 24; 10(1):38-43. PubMed ID: 11366522
    [Abstract] [Full Text] [Related]

  • 9. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
    Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA.
    J Infect Dis; 1999 Jun 24; 179(6):1375-81. PubMed ID: 10228057
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, Dehertogh P, Moreno S, NELSANE Study.
    AIDS Res Hum Retroviruses; 2001 Jan 20; 17(2):93-8. PubMed ID: 11177388
    [Abstract] [Full Text] [Related]

  • 11. Protease inhibitors and prevention of cross resistance.
    Levin J.
    AIDS Treat News; 1995 Oct 06; (no 232):1-3. PubMed ID: 11362875
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Development of HIV protease inhibitors: a survey.
    Ren S, Lien EJ.
    Prog Drug Res; 1998 Oct 06; 51():1-31. PubMed ID: 9949858
    [Abstract] [Full Text] [Related]

  • 14. What they say about: protease inhibitors.
    Posit Aware; 2000 Oct 06; 11(1):48-54. PubMed ID: 11366351
    [Abstract] [Full Text] [Related]

  • 15. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
    Zachary KC, Hanna GJ, D'Aquila RT.
    Clin Infect Dis; 2001 Dec 15; 33(12):2075-7. PubMed ID: 11700580
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.
    Para MF, Glidden DV, Coombs RW, Collier AC, Condra JH, Craig C, Bassett R, Leavitt R, Snyder S, McAuliffe V, Boucher C.
    J Infect Dis; 2000 Sep 15; 182(3):733-43. PubMed ID: 10950766
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
    Lalezari JP, Ward DJ, Tomkins SA, Garges HP.
    J Antimicrob Chemother; 2007 Jul 15; 60(1):170-4. PubMed ID: 17491001
    [Abstract] [Full Text] [Related]

  • 20. Double protease inhibitor regimens with amprenavir show promise.
    AIDS Patient Care STDS; 1998 Apr 15; 12(4):317-8. PubMed ID: 11361962
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.